| DON'T BUY | 0.130 | Peter Hodson | Thinks it’s a horrible company. Last year they did $120 million of financing at $0.65. The $1 stock immediately plunged to $0.65. Last week they announced a $20 million financing at $0.15 convertible debenture. Has gone through $120 million in 12 months. | 2007-11-26 | |
| DON'T BUY | 3.750 | Peter Hodson | Thinks it will bounce around a little bit. Not his favourite name. Continue to spend a lot of money and ultimately will have to come back to the market, perhaps some time next year. With the state of biotechs, both large and small, it is not a sector he would want to be in right now. Doesn't like the management. | 2005-04-07 | |
| WEAK BUY | 4.700 | Peter Hodson | Had a problem with nausea on their drug. Data is improving. Starting to fix the nausea problem. A very effective product. Did another financing, so they are well cashed up. Not the best management team. | 2005-02-07 | |
| WAIT | 4.910 | Werner Muehelemann | Was concerned when their drug was causing nausea, so they sold. Thinks they will have to do a lot of work. Will watch to see if they can solve the problem. | 2005-01-06 | |
| DON'T BUY | 3.490 | Peter Hodson | The nausea under the diabetes drug is fixable under certain conditions, but the question is can the do it. If they can fix, it's a very robust product and will have a very big market. | 2004-11-04 | |
| WAIT | 2.800 | Peter Hodson | Sold his holdings because of the convertible debenture issued. Too early to go back in. Expect their will be a lot of tax selling towards the end of the year and will look at it at that time. | 2004-09-24 | |
| DON'T BUY | 3.400 | Andrew McCreath | The drop out rate on their diabetes drug was higher than expected. Wasn't happy the way management disseminated the information. Dead money in the near term. | 2004-09-08 | |
| WEAK BUY | 3.990 | Martin Hubbes, CFA | Feels there is a potential drug here. Probably is near its bottom. A fair risk/reward. They are trying a new formulation re: nausea of the drugs they tested in phase 2 trials. Also waiting for a combination trial. | 2004-08-23 | |
| DON'T BUY | 3.610 | Bruce Campbell | Needs to know more before he would buy. Have to see better results in the future. Buy when it's rising. | 2004-08-06 | |
| TOP PICK | 3.990 | Ed Ho | Not really happy with management. Took a big drop and is an interesting buy now. The drug works. Potential of being in phase three next year. Really cheap. | 2004-07-30 | |
| DON'T BUY | 4.270 | Michael Smedley | Not sure you should buy it at this time. You want to hold it when there is a possibility of approval being given for their product. | 2004-07-28 | |
| DON'T BUY | 4.800 | David Driscoll | A negative report on patient's reactions created a drop in the stock. Drugs in phase one or phase two trials can be very volatile. Prefers larger companies. | 2004-07-15 | |
| BUY | 11.500 | Peter Hodson | An announcement is coming out next week and he thinks the news will be good, but would like it to be great. Speculative. Good management and balance sheet. | 2004-07-08 | |
| BUY | 11.720 | Michael Smedley | Stock has come off since they announced the successful trials on their diabetes applications. There is some risk, but has potential. | 2004-05-12 | |
| DON'T BUY | 13.800 | Glenn Paradis, BA, CFA | Has had a huge move. Has moved too far, too fast. Solid programs. Expensive. | 2004-04-22 | |
| WAIT | 12.800 | Peter Hodson | Coming-out with clinical trial results on Monday. Stock has had a huge run in anticipation of this. Good company, but wait for the results. | 2004-04-08 | |
| DON'T BUY | 13.000 | Michael Smedley | A very interesting company but has had a big run. Would look elsewhere. | 2004-04-07 | |
| SELL | 13.550 | Andrew McCreath | An incredibly expensive stock. Market has been expecting some trial news that they believe will cause drug companies to want to own the Company. Risky. | 2004-03-25 | |
| PAST TOP PICK | 21.150 | Peter Hodson | (A top pick on Dec 4/03. Up 156%.) Still likes of a lot. Will probably go into the index this month. A couple of analysts are calling it the next RIM. The market for their diabetes product is absolutely gigantic. | 2004-03-02 | |
| HOLD | 9.170 | Peter Hodson | Has great technology. Had a huge run. They have a phase two trial going on for diabetes and if it works, the stock is $20. If not, could go back to $.50. Caution. | 2004-01-23 | |
| TOP PICK | 4.720 | Peter Hodson | Product had a wide platform of multiple uses and a couple of products didn't work so stock dropped drastically. Now using it with a diabetes product, which is getting a lot of attention. A trading stock. Trade at $7/8 before the trial results come out | 2003-12-04 | |
| WEAK BUY | 4.370 | Robert Floyd | New issue gave them needed cash. In the process of digesting it. Now looking for some better results in the diabetes applications. Could be a joint venture down the road. Volatile area. | 2003-09-22 | |
| DON'T BUY | 1.600 | Lou Schizas | Up 317% on a year to date basis. Seems to be finding support around the $1.60 level. May be a little high now. | 2003-06-19 | |
Experts that have talked about ConjuChem Inc
Rss Top Picks Feed
